指南&解读

订阅

MedSci主页 / 所有栏目 / 指南&解读

靶向给药系统研究进展

2010-08-23 MedSci原创 MedSci原创

靶向给药
关注

靶向给药系统研究进展.ppt

靶向给药系统研究进展.ppt

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2880, encodeId=b5c8288022, content=有用的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=138938774, createdName=ichenwei, createdTime=Mon Aug 29 14:40:00 CST 2011, time=2011-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038313, encodeId=24a32038313f0, content=<a href='/topic/show?id=8736999382a' target=_blank style='color:#2F92EE;'>#靶向给药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99938, encryptionId=8736999382a, topicName=靶向给药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Thu Oct 28 11:47:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380295, encodeId=b3ac13802950f, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Aug 25 12:47:00 CST 2010, time=2010-08-25, status=1, ipAttribution=)]
    2011-08-29 ichenwei

    有用的资料

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2880, encodeId=b5c8288022, content=有用的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=138938774, createdName=ichenwei, createdTime=Mon Aug 29 14:40:00 CST 2011, time=2011-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038313, encodeId=24a32038313f0, content=<a href='/topic/show?id=8736999382a' target=_blank style='color:#2F92EE;'>#靶向给药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99938, encryptionId=8736999382a, topicName=靶向给药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Thu Oct 28 11:47:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380295, encodeId=b3ac13802950f, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Aug 25 12:47:00 CST 2010, time=2010-08-25, status=1, ipAttribution=)]
    2010-10-28 ms7405317358118777

    #靶向给药#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2880, encodeId=b5c8288022, content=有用的资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=138938774, createdName=ichenwei, createdTime=Mon Aug 29 14:40:00 CST 2011, time=2011-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038313, encodeId=24a32038313f0, content=<a href='/topic/show?id=8736999382a' target=_blank style='color:#2F92EE;'>#靶向给药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99938, encryptionId=8736999382a, topicName=靶向给药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/xkicoVBAnV4HxvdCqC1viaW8wdLQdN9hVP9icgqqDsxC6UVPjfhogdfc2iaU1xNUMVlFl5QicicWrjWQBTsVye5ngOQQ/132, createdBy=f92f2500185, createdName=ms7405317358118777, createdTime=Thu Oct 28 11:47:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380295, encodeId=b3ac13802950f, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Aug 25 12:47:00 CST 2010, time=2010-08-25, status=1, ipAttribution=)]
    2010-08-25 mashirong

    #研究进展#

    0